Loading
Latest filing published 11 Aug 2017 for Sonoma Pharmaceuticals, Inc., €2,707.
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Marc Umscheid is a declared insider of Sonoma Pharmaceuticals, Inc., with filings sourced from SEC (Form 4). Over a trading history stretching from 6 March 2017 to 10 August 2017, the count stands at 3 filings.
Every open-market trade on record is a purchase: 2 purchases worth €7,523, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 1 share grant.
The newest entry dates from 11 August 2017: an open-market purchase of €2,707, in Sonoma Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations